Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer Cells

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Statins are investigated for anti-tumor properties, including cell death induction and metastasis inhibition.
• The precise anti-tumor mechanisms of statins, particularly in prostate cancer, remain incompletely understood.
• This study explores simvastatin's potential as a novel treatment for castration-resistant prostate cancer (CRPC), focusing on its impact on cellular autophagy.

Purpose of the Study:

• To investigate the effects of simvastatin on prostate cancer cell proliferation and autophagy.
• To determine if simvastatin can be a novel therapeutic agent for castration-resistant prostate cancer (CRPC).
• To assess the combined effects of simvastatin and an autophagy inducer (rapamycin) on prostate cancer cells.

Main Methods:

• Prostate cancer cell lines (PC-3, LNCaP-LA, DU145, 22RV1) were treated with simvastatin.
• Cell proliferation was assessed using MTS assay and cell counting.
• Autophagy was measured via autophagosome staining and LC-3 protein quantification (Western blot).
• Microarray analysis was performed on PC-3 cells treated with simvastatin.

Main Results:

• Simvastatin exhibited a significant, concentration-dependent inhibition of prostate cancer cell growth.
• Simvastatin administration led to a significant increase in autophagy across all tested cell lines.
• Co-administration of simvastatin and rapamycin, at non-inhibitory concentrations of rapamycin alone, significantly amplified autophagy induction and enhanced the growth-inhibitory effect on PC-3 cells.

Conclusions:

• Simvastatin effectively induces autophagy and suppresses proliferation in prostate cancer cell lines.
• The combination of simvastatin and rapamycin synergistically enhances autophagy and prostate cancer cell growth inhibition.
• Targeting this simvastatin-induced autophagy pathway presents a potential novel therapeutic strategy for prostate cancer.